Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654152 | 0.90 | MAPT (1.00) | MAPTHPGDL3MBTL1ALDH1A1POLB | |
| SCHEMBL843841 | 0.82 | MAPT (0.55) | MAPTHPGDALDH1A1GAASMN1; SMN2 | |
| SCHEMBL844895 | 0.82 | MAPT (0.55) | MAPTHPGDALDH1A1GAAKDM1A | |
| SCHEMBL13067230 | 0.82 | HTT (0.59) | MAPTHPGDALDH1A1POLBGAA | |
| SCHEMBL10517551 | 0.81 | MAPT (0.62) | MAPTHPGDALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL13067211 | 0.80 | HTT (0.58) | MAPTHPGDALDH1A1POLBGAA | |
| SCHEMBL12283046 | 0.79 | HTT (0.56) | MAPTL3MBTL1ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL13067223 | 0.79 | HTT (0.79) | MAPTHPGDALDH1A1GAAKDM1A | |
| SCHEMBL5312755 | 0.79 | HTT (0.56) | MAPTHPGDL3MBTL1ALDH1A1GAA | |
| SCHEMBL1520968 | 0.79 | SMN1; SMN2 (0.57) | MAPTHPGDL3MBTL1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| WO-2010132999-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | CHLORION PHARMA, INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | MAPT 385/4885HPGD 342/4885L3MBTL1 4706/4885 |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | MAPT 385/4885HPGD 342/4885L3MBTL1 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.